Traders should anticipate continued share price pressure due to the significant dilution from this offering. Monitor the company's cash runway and progress toward FDA approval for INO-3107, as these will be key factors in determining whether the capital raise provides sufficient runway to achieve value inflection points or merely delays potential insolvency.
INO drugs
INO drug pipeline →How the stock moved after the report
BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 6 $1.13entry
- T+1 · 7mo ago −7.08%α −7.14% · $1.05
- T+5 · 7mo ago −3.54%α −7.67% · $1.09
- T+20 · 7mo ago +0.89%α −8.10% · $1.14
- T+60 · 5mo ago +5.31%α −8.16% · $1.19
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Inovio Pharmaceuticals entered into a material definitive agreement (Item 1.01) to conduct a public offering of 12.5 million shares of common stock and accompanying warrants, raising approximately $16.45 million in gross proceeds before expenses. This offering, combined with a recent capital raise, indicates the company is securing funds amid ongoing uncertainty about its ability to continue as a going concern, leading to significant shareholder dilution.
Key Financial Metrics
Key Facts
- Inovio Pharmaceuticals is conducting a public offering of 12,500,000 shares of common stock, Series A warrants to purchase up to 12,500,000 shares, and Series B warrants to purchase up to 12,500,000 shares.
- The combined public offering price is $1.40 per share and accompanying warrants, with gross proceeds of $17.5 million and net proceeds of approximately $16.45 million after underwriting discounts.
- The offering includes an over-allotment option for up to an additional 1,875,000 shares and warrants.
- This capital raise follows a recent 424B5 filing, indicating a pattern of dilutive financing to fund operations.
- The company has acknowledged substantial doubt about its ability to continue as a going concern.
Financial Impact
Raises $16.45 million in net proceeds through issuance of 12.5 million common shares and 25 million warrants, causing immediate and significant shareholder dilution.
Risk Factors
- Substantial shareholder dilution from the issuance of new shares and warrants
- Ongoing uncertainty about the company's ability to continue as a going concern
- Risk that the raised capital will not be sufficient to achieve commercial milestones or secure additional funding
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-142885 |
| Document: d137120dex42.htm | 0001193125-26-142885 |
| Document: d137120dex43.htm | 0001193125-26-142885 |
| Document: d137120dex41.htm | 0001193125-26-142885 |
Track record
20 reports on INO
7 of 13 bullish or bearish reports moved the stock their way by T+5. Best: +46.23% at T+20 after the Jul 2, 2026 report. 8 of 14 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 4/10 Entry $1.39 Now $1.40 +0.72% settles Nov 24
- Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $1.40 Now $1.40 −0.01% settles Nov 24
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $1.41 Now $1.40 −0.71% settles Nov 23
- Nov 10, 20266d ago 8-K Bearish 5/10 Entry $1.48 Now $1.40 +5.08% settles Nov 18
- Nov 9, 20267d ago 8-K Bearish 5/10 Entry $1.51 to $1.40 Now $1.40 +7.28% ▲ +7.28% +5.59% vs SPY
- Nov 6, 202610d ago 424B5 Bearish 5/10 Entry $1.51 to $1.40 Now $1.40 +7.28% ▲ +7.28% +5.59% vs SPY
- Nov 5, 202611d ago Press Release Bearish 6/10 Entry $1.22 to $1.43 Now $1.40 −15.23% ▼ −17.70% −15.10% vs SPY
- Nov 5, 202611d ago 8-K Bearish 5/10 Entry $1.22 to $1.43 Now $1.40 −15.23% ▼ −17.70% −15.10% vs SPY
- Nov 5, 202611d ago 424B5 Bearish 4/10 Entry $1.22 to $1.43 Now $1.40 −15.23% ▼ −17.70% −15.10% vs SPY
- Nov 5, 202611d ago Press Release Bearish 4/10 Entry $1.22 to $1.43 Now $1.40 −15.23% ▼ −17.70% −15.10% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers